Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta-analysis.

He F, Chen W, Xu W, Liu D, Xiao Z, Tang Y, Lin Z, Liao Y, Bin J, Chen G, Chen Y

Diabetes, obesity & metabolism21 Nov 2022Cited by 15 (Europe PMC)

PMID36314246DOI10.1111/dom.14908PepBankPUB-36314246

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with or without type 2 diabetes, liraglutide significantly decreased visceral fat versus control in a meta-analysis of randomized trials.
In plain wordsIn adults with or without type 2 diabetes, trials pooled together showed liraglutide reduced visceral fat compared with controls.
Peptide
Liraglutide
Outcome
DecreaseVisceral fat
Study
n: not reported in source
Comparator
Control groups
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
SMD
−0.72 SMD
visceral fat
Source sentences
Summary
Liraglutide could significantly decrease visceral fat [standard mean difference (SMD) = -0.72, 95% confidence interval (CI; -1.12, -0.33)], liver fat [SMD = -0.78, 95% CI (-1.24, -0.32)] and body mass index [weighted mean difference = -1.44, 95% CI (-1.95, -0.92)] in adult patients with or without T…
2 context sentences(design, population, supporting numbers)
Summary · context
Four databases were searched up to 6 May 2022 for randomized clinical trials assessing the effect of liraglutide on visceral and ectopic fat.
Summary · context
Sixteen randomized clinical trials with, in total, 845 participants were included in the meta-analysis.
Report a problemFND-3631424601
02HumanSystematic reviewEfficacy outcome
In adults with or without type 2 diabetes, liraglutide significantly decreased liver fat versus control in a meta-analysis of randomized trials.
In plain wordsIn adults with or without type 2 diabetes, trials pooled together showed liraglutide reduced liver fat compared with controls.
Peptide
Liraglutide
Outcome
DecreaseLiver fat
Study
n: not reported in source
Comparator
Control groups
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
SMD
−0.78 SMD
liver fat
Source sentences
Summary
Liraglutide could significantly decrease visceral fat [standard mean difference (SMD) = -0.72, 95% confidence interval (CI; -1.12, -0.33)], liver fat [SMD = -0.78, 95% CI (-1.24, -0.32)] and body mass index [weighted mean difference = -1.44, 95% CI (-1.95, -0.92)] in adult patients with or without T…
2 context sentences(design, population, supporting numbers)
Summary · context
Four databases were searched up to 6 May 2022 for randomized clinical trials assessing the effect of liraglutide on visceral and ectopic fat.
Summary · context
Sixteen randomized clinical trials with, in total, 845 participants were included in the meta-analysis.
Report a problemFND-3631424602
03HumanSystematic reviewEfficacy outcome
In adults with or without type 2 diabetes, liraglutide significantly decreased body mass index versus control in a meta-analysis of randomized trials.
In plain wordsIn adults with or without type 2 diabetes, trials pooled together showed liraglutide lowered body mass index compared with controls.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Comparator
Control groups
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
WMD
−1.44 WMD
body mass index
Source sentences
Summary
Liraglutide could significantly decrease visceral fat [standard mean difference (SMD) = -0.72, 95% confidence interval (CI; -1.12, -0.33)], liver fat [SMD = -0.78, 95% CI (-1.24, -0.32)] and body mass index [weighted mean difference = -1.44, 95% CI (-1.95, -0.92)] in adult patients with or without T…
2 context sentences(design, population, supporting numbers)
Summary · context
Four databases were searched up to 6 May 2022 for randomized clinical trials assessing the effect of liraglutide on visceral and ectopic fat.
Summary · context
Sixteen randomized clinical trials with, in total, 845 participants were included in the meta-analysis.
Report a problemFND-3631424603
04HumanSystematic reviewEfficacy outcome
In adults with or without type 2 diabetes, the reduction of epicardial fat by liraglutide was not statistically significant in a meta-analysis.
In plain wordsIn adults with or without type 2 diabetes, pooled trials found no statistically significant drop in heart-surrounding fat with liraglutide.
Peptide
Liraglutide
Outcome
No significant changeEpicardial fat
Study
n: not reported in source
Comparator
Control groups
Outcome group
Body weight · Cardiovascular
Studied dose
Dose not stated
Measurements
SMD
−0.74 SMD
epicardial fat
Source sentences
Summary
However, reduction of epicardial fat by liraglutide [SMD = -0.74, 95% CI (-1.82, 0.34)] was not statistically significant.
2 context sentences(design, population, supporting numbers)
Summary · context
Four databases were searched up to 6 May 2022 for randomized clinical trials assessing the effect of liraglutide on visceral and ectopic fat.
Summary · context
Sixteen randomized clinical trials with, in total, 845 participants were included in the meta-analysis.
Report a problemFND-3631424604
05HumanSystematic reviewEfficacy outcome
In a subgroup analysis of trials, an adequate liraglutide dosage (at least 1.8 mg/day) and treatment of 16 to 40 weeks were decisive for reducing visceral fat.
In plain wordsIn pooled trials, liraglutide reduced visceral fat effectively only with a high enough dose and 16 to 40 weeks of treatment.
Peptide
Liraglutide
Outcome
DecreaseVisceral fat by dose and treatment duration (subgroup)
Study
n: not reported in source
Comparator
Control groups
Outcome group
Body weight · Metabolic and weight
Studied dose
≥1.8 mg/day · 16 to 40 weeksAs given in this study (human).
Source sentences
Summary
Subgroup analysis revealed that an adequate dosage (≥1.8 mg/day) and appropriate duration of treatment (ranging from 16 to 40 weeks) were the decisive factors for liraglutide to reduce visceral fat effectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Four databases were searched up to 6 May 2022 for randomized clinical trials assessing the effect of liraglutide on visceral and ectopic fat.
Summary · context
Sixteen randomized clinical trials with, in total, 845 participants were included in the meta-analysis.
Report a problemFND-3631424605
06HumanSystematic reviewSafety outcome
In the pooled trials, mild gastrointestinal reactions were the main adverse event of liraglutide.
In plain wordsIn pooled trials, the main side effect of liraglutide was mild stomach and gut reactions.
Peptide
Liraglutide
Outcome
Not applicableAdverse events
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Mild gastrointestinal reactions were the main adverse event of liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Four databases were searched up to 6 May 2022 for randomized clinical trials assessing the effect of liraglutide on visceral and ectopic fat.
Summary · context
Sixteen randomized clinical trials with, in total, 845 participants were included in the meta-analysis.
Report a problemFND-3631424606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.